Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data
This article has been corrected.
VIEW CORRECTIONPublication: Journal of Comparative Effectiveness Research
Abstract
Aim: Late-onset Pompe disease is characterized by progressive loss of muscular and respiratory function. Until recently, standard of care was enzyme replacement therapy (ERT) with alglucosidase alfa. Second-generation ERTs avalglucosidase alfa (aval) and cipaglucosidase alfa with miglustat (cipa+mig) are now available. Without head-to-head trials comparing aval with cipa+mig, an indirect treatment comparison is informative and timely for understanding potential clinical differentiation. Materials & methods: A systematic literature review was performed to identify relevant studies on cipa+mig and aval. Using patient-level and aggregate published data from randomized controlled trials (RCTs) and phase I/II and open-label extension (OLE) trials, a multi-level network meta-regression was conducted, adjusting for various baseline covariates, including previous ERT duration, to obtain relative effect estimates on 6-minute walk distance (6MWD, meters [m]) and forced vital capacity (FVC, % predicted [pp]). Analyses of two networks were conducted: Network A, including only RCTs, and network B, additionally including single-arm OLE and phase I/II studies. Results: Network B (full evidence analysis) showed that cipa+mig was associated with a relative increase in 6MWD (mean difference 28.93 m, 95% credible interval [8.26–50.11 m]; Bayesian probability 99.7%) and FVC (2.88 pp [1.07–4.71 pp]; >99.9%) compared with aval. The comparison between cipa+mig and aval became more favorable for cipa+mig with increasing previous ERT duration for both end points. Analysis of network A showed that cipa+mig was associated with a relative decrease in 6MWD (-10.02 m [-23.62 to 4.00 m]; 91.8%) and FVC (-1.45 pp [-3.01 to 0.07 pp]; 96.8%) compared with aval. Conclusion: Cipa+mig showed a favorable effect versus aval when all available evidence was used in the analysis.
Supplementary Material
File (supplementary materials.docx)
- Download
- 1.16 MB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Kishnani PS, Steiner RD, Bali D et al. Pompe disease diagnosis and management guideline. Genet. Med. 8(5), 267–288 (2006).
2.
Schoser B, Roberts M, Byrne BJ et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase III trial. Lancet Neurol. 20(12), 1027–1037 (2021).
•• This paper summarizes the results of the phase III PROPEL trial and shows that results on the primary and key secondary end points, 6MWD and FVC % predicted, respectively, were better in ERT-experienced patients.
3.
Huggins E, Holland M, Case LE et al. Early clinical phenotype of late onset Pompe disease: lessons learned from newborn screening. Mol. Genet. Metab. 135(3), 179–185 (2022).
4.
Park KS. Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database. Mol. Genet. Metab. Rep. 27, 100734 (2021).
5.
van der Ploeg AT, Clemens PR, Corzo D et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N. Engl. J. Med. 362(15), 1396–1406 (2010).
6.
Food and Drug Administration. Nexviazyme™, Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761194s000lbl.pdf (2021).
7.
European Medicines Agency. Nexviadyme, Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/nexviadyme-epar-product-information_en.pdf (2022).
8.
European Medicines Agency. Pombiliti, Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/pombiliti-epar-product-information_en.pdf (2023).
9.
European Medicines Agency. Opfolda, Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/opfolda-epar-product-information_en.pdf (2023).
10.
Food and Drug Administration. Pombiliti™, Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761204s000lbl.pdf (2023).
11.
Food and Drug Administration. Opfolda™, Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215211s000lbl.pdf (2023).
12.
Singh A, Debnath R, Saini A et al. Cipaglucosidase alfa-atga: unveiling new horizons in Pompe disease therapy. Health Sci. Rev. 11, 100160 (2024).
13.
Diaz-Manera J, Kishnani PS, Kushlaf H et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a Phase III, randomised, multicentre trial. Lancet Neurol. 20(12), 1012–1026 (2021).
• This paper summarizes the results of the phase III COMET trial and shows that, in enzyme replacement therapy (ERT)-naive patients, aval performs better than alglu on the primary and key secondary end points, forced vital capacity (FVC) % predicted and 6-minute walk distance (6MWD), respectively.
14.
Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med. Decis. Making 33(5), 607–617 (2013).
15.
Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23(20), 3105–3124 (2004).
16.
Phillippo DM, Ades AE, Dias S et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making. 38(2), 200–211 (2018).
17.
Mozaffar T, Schoser B, Kishnani P et al. Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label phase I/II study (ATB200-02) (S48.007). Neurology 100(17 Suppl. 2), (2023).
18.
Dimachkie MM, Barohn RJ, Byrne B et al. Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset Pompe disease. Neurology 99(5), e536–e548 (2022).
•• This study presents long-term results on aval in ERT-naive (n = 10) and ERT-experienced (n = 14) patients from the NEO-1/-EXT trial.
19.
Signorovitch JE, Wu EQ, Yu AP et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 28(10), 935–945 (2010).
20.
Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics 33(6), 537–549 (2015).
21.
Phillippo DM, Dias S, Ades AE et al. Multilevel network meta-regression for population-adjusted treatment comparisons. J. R. Stat. Soc. Ser. A Stat. Soc. 183(3), 1189–1210 (2020).
•• This paper proposes a new indirect treatment comparison (ITC) method that is able to provide relative effect estimates for any target population of interest, not only for the population of the comparator trial and was applied in our study.
22.
Byrne BJ, Kishnani PS, Case LE et al. Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol. Genet. Metab. 103(1), 1–11 (2011).
23.
Semplicini C, De Antonio M, Taouagh N et al. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry. J. Inherit. Metab. Dis. 43(6), 1219–1231 (2020).
24.
Leahy J, Thom H, Jansen JP et al. Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: assessing the impact. Stat. Med. 38(14), 2505–2523 (2019).
•• This paper lays out how single-arm evidence can be incorporated into an network meta-analysis (NMA by matching the (aggregate) baseline characteristics of the single-arm trial to one of the comparator arms of the randomized trials already included in the network.
25.
Thom H, Leahy J, Jansen JP. Network meta-analysis on disconnected evidence networks when only aggregate data are available: modified methods to include disconnected trials and single-arm studies while minimizing bias. Med. Decis. Making. 42(7), 906–922 (2022).
26.
Welton NJ, Phillippo DM, Owen R et al. CHTE2020 sources and synthesis of evidence; update to evidence synthesis methods. https://www.sheffield.ac.uk/sites/default/files/2022-02/CHTE-2020_final_20April2020_final.pdf (2020).
27.
Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).
28.
Sterne JAC, Savović J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019).
29.
Sterne JAC, Hernán MA, Reeves BC et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ 355, i4919 (2016).
30.
Phillippo DM. multinma: Bayesian network meta-analysis of individual and aggregate data. https://zenodo.org/record/6323335 (2022).
31.
Stan Development Team. Stan modeling language users guide and reference manual, Version 2.33. https://mc-stan.org (2022).
32.
R Core Team. R: a language and environment for statistical computing. https://www.r-project.org/ (2019).
33.
Phillippo DM. R package multinma. https://cran.rstudio.com/web/packages/multinma/index.html (2023).
34.
Cabello JF, Marsden D. Pompe disease: clinical perspectives. Orphan Drugs Res. Rev. 7, 1–10 (2016).
35.
Dornelles AD, Junges APP, Pereira TV et al. A systematic review and meta-analysis of enzyme replacement therapy in late-onset Pompe disease. J. Clin. Med. 10(21), 4828 (2021).
36.
Papadimas GK, Anagnostopoulos C, Xirou S et al. Effect of long term enzyme replacement therapy in late onset Pompe disease: a single-centre experience. Neuromuscul. Disord. 31(2), 91–100 (2021).
37.
Baek RC, Palmer R, Pomponio RJ et al. The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa. Mol. Genet. Metab. Rep. 8, 48–50 (2016).
38.
American Statistical Association. American Statistical Association releases statement on statistical significance and p-values: provides principles to improve the conduct and interpretation of quantitative science. https://www.amstat.org/asa/files/pdfs/p-valuestatement.pdf (2016).
39.
Sterne JAC, Davey Smith G. Sifting the evidence-what's wrong with significance tests? BMJ 322(7280), 226–231 (2001).
40.
Rhodes KM, Turner RM, Higgins JPT. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J. Clin. Epidemiol. 68(1), 52–60 (2015).
• This paper provides predictive distributions for particular disease areas and end points that were included as prior distributions into the random-effects (RE) models applied in our study.
41.
Hoaglin DC, Hawkins N, Jansen JP et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 14(4), 429–437 (2011).
42.
Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J. R. Stat. Soc. 64(4), 583–639 (2002).
43.
Haeussler K, Wang X, Winfree KB et al. Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis. Future Oncol. 18(16), 2007–2028 (2022).
44.
Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64(2), 163–171 (2011).
45.
van der Ploeg AT, Barohn R, Carlson L et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol. Genet. Metab. 107(3), 456–461 (2012).
46.
van der Ploeg A, Carlier PG, Carlier R-Y et al. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY Study. Mol. Genet. Metab. 119(1–2), 115–123 (2016).
47.
Sarah B, Giovanna B, Emanuela K et al. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis. J. Neurol. 269(2), 733–741 (2022).
48.
Schoser B, Stewart A, Kanters S et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J. Neurol. 264(4), 621–630 (2017).
49.
Byrne BJ, Schoser B, Kishnani PS et al. Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02). J. Neurol. 271(4), 1787–1801. (2024).
50.
Kishnani PS, Diaz-Manera J, Kushlaf H et al. Efficacy and safety of avalglucosidase alfa in participants with late-onset pompe disease after 145 weeks' treatment during the COMET trial. 19th Annual WORLDSymposium™. Orlando, FL, USA (22–26 February 2023).
• This study presents open-label extension (OLE) results until Week 145 of the COMET trial and provides the second source of evidence on the effect of aval in ERT-experienced patients with late-onset Pompe disease (LOPD) (those who switched from alglu to aval after 49 weeks of treatment).
51.
Mozaffar T, Byrne BJ, Diaz-Manera J et al. Long-term efficacy and safety of cipaglucosidase alfa/miglustat in patients with Pompe disease: a phase III open-label extension study (ATB200-07). MDA Clinical & Scientific Conference. Dallas, TX, USA (19–22 March 2023).
52.
Brudvig JJ, Tuske S, Castelli J, Weimer JM. Comments on: increasing enzyme mannose-6-phosphate levels but not miglustat coadministration enhances the efficacy of enzyme replacement therapy in Pompe mice. J. Pharmacol. Exp. Ther. 389(3), 310–312 (2024).
53.
George K, Anding A. Response to Comments on “Increasing enzyme mannose-6-phosphate levels but not miglustat coadministration enhances the efficacy of enzyme replacement therapy in Pompe mice”. J. Pharmacol. Exp. Ther. 389(3), 313–314 (2024).
54.
Selvan N, Mehta N, Venkateswaran S et al. Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase. J. Biol. Chem. 296, 100769 (2021).
55.
Pena LDM, Barohn RJ, Byrne BJ et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscul. Disord. 29(3), 167–186 (2019).
56.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 14(1), 135 (2014).
57.
Schoser B, Kishnani P, Bratkovic D et al. FP.17 Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label phase I/II study (ATB200-02). Neuromuscul. Disord. 32, S73 (2022).
58.
Raza S, Keyzor I, Shohet S et al. POSA283 Differential appraisal of functional outcome measures by health technology assessment (HTA) agencies when reviewing therapies for rare muscular, skeletal and neurodegenerative disorders. Value Health. 25(1), S175 (2022).
59.
Roberts M, Proskorovsky I, Guyot P et al. Late-onset Pompe disease patients treated with avalglucosidase alfa show favorable results compared with cipaglucosidase alfa plus miglustat: indirect treatment comparison. 19th Annual WORLDSymposium™. Orlando, FL, USA (22–26 February 2023).
Information & Authors
Information
Published In
Copyright
© 2024 Amicus Therapeutics Inc. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 28 March 2024
Accepted: 30 August 2024
Published online: 17 September 2024
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data. (2024) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2024-0045
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Robin Lachmann, Advances in Therapeutics—Enzyme Replacement Therapy: Long‐Term Evaluation and New Approaches, Journal of Inherited Metabolic Disease, 10.1002/jimd.70166, 49, 2, (2026).
- Mireia Claramunt-Molet, Jordi Pegueroles, Ariadna Pi-Cervera, Mari Rico, Sebastian Idelsohn-Zielonka, Cristina Domínguez-González, Manuela Corti, Virgilia Antón, Stephanie M. Salabarria, Karen Wong, Meredith K. James, Barry J. Byrne, Jordi Díaz-Manera, Gait analysis reveals new outcome measures for monitoring disease progression in individuals with late-onset Pompe disease, Journal of NeuroEngineering and Rehabilitation, 10.1186/s12984-026-01898-8, (2026).
- Shuai Fu, Noemi Hummel, Simon Shohet, Neil Johnson, Alasdair MacCulloch, Jeff Castelli, William Kerr, Brian Fox, Vera Gielen, Comparing the efficacy of cipaglucosidase alfa plus miglustat with alglucosidase alfa for late-onset Pompe disease: an expanded network meta-analysis utilizing patient-level and aggregate data, Journal of Comparative Effectiveness Research, 10.57264/cer-2025-0174, 15, 3, (2026).
- Mark Corbett, Chinyereugo Umemneku-Chikere, Sarah Nevitt, Nyanar Jasmine Deng, Matthew Walton, Helen Fulbright, Chong Yew Tan, Robin Lachmann, Rachel Churchill, Robert Hodgson, Enzyme replacement therapy compared with best supportive care for the treatment of Pompe Disease: a systematic review and network meta-analysis, Health Technology Assessment, 10.3310/GJRH0730, (1-58), (2026).
- Misha Khan, Zainab Awan, Eesha Asghar Ali, Mufliha Ibrahim, Farhana Riaz, Eeshal Zulfiqar, Ajay Kumar, Tariq Mahmood Khan, Samar A. Amer, New advances in treating late-onset Pompe Disease: A narrative review, European Journal of Pediatrics, 10.1007/s00431-025-06669-6, 185, 1, (2025).
- Mark E. Roberts, Irina Proskorovsky, Patricia Guyot, Pragya Shukla, Nathan Thibault, Alaa Hamed, Ruth Pulikottil-Jacob, Lasair O’Callaghan, Laurence Pollissard, An Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe Disease, Advances in Therapy, 10.1007/s12325-025-03301-9, 42, 11, (5578-5599), (2025).
- Mark Corbett, Chinyereugo Umemneku-Chikere, Sarah Nevitt, Nyanar Jasmine Deng, Matthew Walton, Helen Fulbright, Chong Yew Tan, Robin Lachmann, Rachel Churchill, Robert Hodgson, Enzyme replacement therapy for the treatment of late onset Pompe disease: A systematic review and network meta-analysis, Orphanet Journal of Rare Diseases, 10.1186/s13023-025-03981-0, 20, 1, (2025).
- Nadine A.M.E. van der Beek, Lianne H. Potters, Benedikt Schoser, Enzyme replacement therapies in adults with Pompe disease: from trials to real-world data, Current Opinion in Neurology, 10.1097/WCO.0000000000001385, 38, 5, (538-545), (2025).
- Hani Kushlaf, Jordi Díaz‐Manera, Drago Bratkovic, Barry J. Byrne, Kristl G. Claeys, Paula R. Clemens, Mazen M. Dimachkie, Priya S. Kishnani, Pascal Laforêt, Mark Roberts, Benedikt Schoser, Antonio Toscano, Jeff Castelli, Fred Holdbrook, Sheela Sitaraman Das, Mitchell Goldman, Tahseen Mozaffar, Switching Enzyme Replacement Therapy for Late‐Onset Pompe Disease From Alglucosidase Alfa to Cipaglucosidase Alfa Plus Miglustat: Post Hoc Effect Size Analysis of PROPEL , Muscle & Nerve, 10.1002/mus.28420, 72, 2, (230-239), (2025).